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Abstract
The DNA damage response (DDR) encompasses multi-step processes by which cells evolve to sense DNA damage,
transduce the signal and initiate the repair of damaged DNA. Ataxia Telangiectasia Mutated (ATM) Kinase, which functions
as the primary sensor and transducer of DNA damage signal, has been demonstrated to play an important role in the DDR
and cancer prevention. Hence, understanding the molecular mechanisms underlying the regulation of ATM has received
much attention. Here, we found that miR-18a was upregulated in both cell lines and patients’ tissue samples of breast
cancer. Furthermore, we demonstrated that ectopically expressing miR-18a downregulated ATM expression by directly
targeting the ATM-39-UTR and abrogated the IR-induced cell cycle arrest. Similar to the effect of ATM siRNA, overexpressing
miR-18a in breast cancer cells reduced the DNA damage repair ability and the efficiency of homologous recombination-
based DNA repair (HRR) and sensitized cells to c-irradiation (IR) treatment. However, inhibition of miR-18a led to
augmentation of DNA damage repair, increase of HRR efficiency and reduced cellular radiosensitivity. Moreover, we showed
that the phorsphorylation level and nuclear foci formation of H2AX and 53BP1, the downstream substrates of ATM kinase,
were significantly deceased in miR-18a overexpressing cells. Taken together, our results uncover a new regulatory
mechanism of ATM expression and suggest that miR-18a might be a novel therapeutic target.
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Introduction
DNA damage response, an intricate signal transduction
pathway, responds to DNA damage by initiating DNA repair or
inducing apoptosis [1]. Amount of evidence has demonstrated that
defects in any of the DDR related genes, which are responsible for
sensing the damage, signal transduction and repairing double
strand breaks (DSBs), could result in chromosomal breaks, fusions,
and translocations, that ultimately to tumorigenesis. For instance,
DDR related genes, such as RFC5, DPB11, MEC1, DDC2,
MEC3, RAD53, CHK1, PDS1, and DUN1, have been reported
to play important role in the maintenance of genomic stability and
dysregulations of these genes were frequently found in many
cancer types [2–5].
ATM (ataxia-telangiectasia mutated), a serine/threonine pro-
tein kinase, functions as a transducer of the DNA damage signal to
the downstream effector machinery. In response to DSBs
induction, ATM protein kinase becomes an active monomer from
inactive dimer in a process involving autophosphorylation on
serine (Ser
1981) [6]. The active ATM rapidly hyperphosphorylates
and activates downstream effecter CHK2 [7]. Furthermore, the
activated CHK2 kinase phosphorylates its key substrates,
CDC25A and CDC25C, which results in cells being arrested in
the S phase or G2/M phases, respectively [8]. Meanwhile, ATM
also hyperphosphorylates H2AX and p53 binding protein 1
(53BP1), upon DNA damage, which then form discrete nuclear
foci at the site of the damaged DNA, which could amplify the
degree of DDR [9–10]. The phosphorylated H2AX (c-H2AX),
one of the earliest ATM-dependent responses to IR, concentrated
on the DNA lesions and formed discrete nuclear foci with
phosphorylated 53BP1 protein, which was critical for recruiting
various DNA repair proteins, such as BRCA1, NBS1, Rad51 and
TopoBP1 [11–13]. ATM deficient cells showed no hyperpho-
sphorylation and reduced foci formation of c-H2AX and 53BP1 in
response to IR compared with cells expressing wild-type ATM,
resulting low DNA repair efficiency [9,14].
ATM was named for the autosomal recessive progressive
neurodegenerative disease, ataxia-telangiectasia (AT), which is
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associated with loss of ATM activity are neurodegeneration,
extreme cellular sensitivity to radiation, immunodeficiency, and a
predisposition to cancer [16]. Constantly, ATM deficient mice
displayed growth retardation, neurologic dysfunction, radiosensi-
tivity, sterility, defects in T lymphocyte maturation and predispo-
sition to cancers with increased levels of hematopoietic malignan-
cies in particular [17]. These phenotypic manifestations in both
AT patients and ATM-deficient mice demonstrate that the
pleiotropic function of ATM kinase is associated with various
biological processes, including DNA repair, G1/S, intra-S and
G2/M checkpoints, apoptosis, translation initiation, gene regula-
tion and telomere maintenance [18]. Consistent with its function,
mutations within ATM or repression of ATM have been found in
multiple cancer types, such as breast cancer, pancreatic cancer,
myeloma, leukemias and lymphomas [19–24]. Hence, under-
standing the molecular mechanisms underlying the regulation of
ATM in cancers has received much attention.
Analysis with two publicly available algorithms (TargetScan and
miRanda), we found that ATM protein kinase is theoretically the
target gene of miR-18a. Furthermore, we demonstrated that
overexpression of miR-18a downregulated ATM expression by
directly targeting the ATM-39-UTR, consequently resulting in
reduction of the DNA damage repair ability and the HRR
efficiency, and an increase in cellular radiosensitivity to IR
treatment. Taken together, these results suggest that miR-18a
plays an important role in the regulation of ATM and may
represent a therapeutic target for cancers and other diseases.
Results
miR-18a Is Overexpressed in Breast Cancer Cell Lines and
Breast Cancer Tissues
Real-time PCR analyses revealed that miR-18a was significantly
overexpressed in all of the 9 examined breast cancer cell lines,
including ZR-75-1, ZR-75-30, SKBR3, T47D, MDA-MB-231,
MDA-MB-435, MDA-MB-453, BT474 and BT-549, as compared
with that in normal breast epithelial cells (NBEC) (Figure 1A).
Furthermore, comparative analysis revealed that miR-18a was
differentially overexpressed in 10 examined tissue samples paired
with adjacent non-cancerous tissues from the same patient
(Figure 1B), indicating that miR-18a is generally upregulated in
breast cancer.
miR-18a Regulates DNA Damage-induced Cell Cycle
Checkpoint
To investigate the biological role of miR-18a on the
development and progression of breast cancer, the impact of
miR-18a on proliferation of breast cancer cells was evaluated using
flow cytometry. As shown in Figure 1C, ectopic expression of miR-
18a dramatically decreased the proportion of cells in the G1/G0
peak and increased the proportion of cells in the S peak in both
breast cancer cells MDA-MB-231 and SKBR3 as compared with
that of negative control (NC) transfected cells. Furthermore,
BrdUrd incorporation assay was performed and showed that the
S-phase fraction with BrdUrd incorporation dramatically in-
creased in MDA-MB-231(47.5%) and SKBR3 (44.7%) cells
ectopically expressing miR-18a, as compared with the NC-
transected control cells (36.2% and 33.7% for MDA-MB-231
and SKBR3 control cells, respectively (Figure 1D), suggesting that
miR-18a is involved in the regulation of cell cycle.
Strikingly, we found that IR-induced cell cycle arrest in MDA-
MB-231 and SKBR3 cells were also abolished by miR-18a
overexpression, as analyzed by the flow cytometry assay, which
indicated that miR-18a expression impaired the changes in cell
proportions pre-IR and post-IR treatment to a lesser extent than
the control cells (Figure 1C). Moreover, the percentage of BrdUrd-
incorporating cells significantly decreased in NC-transfected cells
after IR treatment, whereas no obvious alteration in the
percentage of BrdUrd-incorporating cells in both breast cancer
cell lines transfected with miR-18a pre-IR and post-IR treatment
(Figure 1D), suggesting that miR-18a might contribute to
conquering the DNA synthesis block induced by IR and enhance
the radioresistant DNA synthesis of cells.
miR-18a Suppresses ATM Expression by Targeting 39-UTR
of ATM
To investigate the abrogation mechanism of miR-18a on DNA
damage induced-cell cycle arrest, we then sought to identify the
molecular targets of miR-18a, which might be associated with
DNA damage response. Analysis with the use of two publicly
available algorithms (TargetScan and miRanda) indicated that
ATM protein kinase, which has been demonstrated to be
associated with the regulation of DNA damage-induced cell cycle
checkpoints, is theoretically the target gene of miR-18a (Figure 2A).
As expected, western blotting analysis revealed that the level of
ATM protein was significantly downregulated upon miR-18a
transfection but upregulated when miR-18a was suppressed
(Figure 2B). Furthermore, the ATM 3 `-untranslated region (39-
UTR) fragment containing the miR-18a binding site (RE) was
subcloned into the pEGFP-C3 and pGL3 luciferase reporter
vectors. As shown in Figure 2C, overexpression of miR-18a in
both MDA-MB-231 and SKBR3 breast cancer cell lines
drastically suppressed the GFP protein expression, but not the
expression of GFP-c-tubulin that was used as the transfection
control, suggesting that miR-18a specifically affected the ATM-39-
UTR. Moreover, a consistent and dose-dependent reduction of
luciferase activity was observed upon miR-18a transfection in both
breast cancer cell lines (Figure 2D). However, point mutations in
the tentative miR-18a-binding seed region in the ATM 39-UTR
abrogated the suppressive effect of ATM expression mediated by
miR-18a (Figure 2E). Thus our results demonstrate that ATM is a
bona fide target of miR-18a.
To further examine whether the conclusions above could be
supported by observations in human primary tumors, the
expression levels of miR-18a and ATM were examined in 9
freshly prepared human breast tumor tissues. As shown in
Figure 2F, statistical analysis demonstrated that miR-18a expres-
sion inversely correlated with ATM (r=20.766, P,0.05).
Furthermore, this inverse correlation was also observed in breast
cancer cell lines (r =20.712, P,0.05), as indicated in Figure 1A
and Figure S1. Collectively, these results further supported the
notion that ATM is the target of miR-18a.
miR-18a Impaired the ATM Signaling Pathway
It has been reported that IR treatment could upregulate ATM
expression and consequentially lead to phosphorylation of
checkpoint kinase 2 (CHK2), H2AX and 53BP1 [7–10,25], which
promoted us to further examine the effect of miR-18a on the ATM
downstream target proteins. As shown in Figure 3A, the increased
expression levels of ATM protein and the phosphorylation level of
CHK2 after IR treatment in both breast cancer cell lines were
dramatically abolished by the transfection of miR-18a. Further-
more, Western blotting analysis revealed that ectopic expression of
miR-18a drastically decreased the phosphorylation levels of
H2AX (c-H2AX) and 53BP1 (p-53BP1), which was similar to
the effects of ATM depletion (Figure 3B). This was further
confirmed by an indirect immunofluorescence assay, which
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PLoS ONE | www.plosone.org 2 September 2011 | Volume 6 | Issue 9 | e25454Figure 1. Upregulation of miR-18a abrogated IR-induced cell cycle arrest. A, Real-time PCR analysis of miR-18a expression in normal breast
epithelial cells (NBEC) and breast cancer cell lines, including ZR-75-1, ZR-75-30, SKBR3, T47D, MDA-MB-231, MDA-MB-435, MDA-MB-453, BT474 and
BT-549. B, The expression of miR-18a was examined in 10 paired breast tumor tissues (tumor) and their adjacent normal tissues (normal). The average
miR-18a expression was normalized by U6 expression. Each bar represents the mean of three independent experiments. C, Flow cytometric analysis
of indicated breast cancer cells transduced with miR-18a mimic or NC, treated with or without 2.0 Gy IR. Statistic analysis revealed the proportion
change of cells at each phase of cell cycle from three independent experiments under different miR-18a expression levels with or without IR
treatment, using the algorithm (S
+IR2S
-IR)/S
-IR6100%. D, Representative micrographs (left) and quantification analysis (right) of BrdUrd incorporating-
cells in indicated cells with or without 2.0 Gy IR.
doi:10.1371/journal.pone.0025454.g001
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were significantly reduced in cells that overexpressed miR-18a
(Figure 3C and 3D). Collectively, our results suggested that miR-
18a impaired the ATM-mediated DNA damage signal.
miR-18a Reduces Cell HRR Frequency and Enhances Cell
Radiation Sensitivity
Since it has been demonstrated that ATM plays an important
role in the HRR [26], a DSB-induced HRR assay was performed.
As shown in Figure 4A, similar to the effect of ATM depletion,
overexpressing miR-18a significantly reduced HRR frequency.
However, co-transfection of ATM-targeted siRNA and miR-18a
did not further augment the inhibitory effect of ATM silencing on
HRR (Figure 4A). As HR deficiency could sensitize cells to IR, we
speculated that miR-18a expression would impact cellular
sensitivity to IR treatment. As expected, a clonogenic assay
showed that the overexpression of miR-18a resulted in rendering
both MDA-MB-231 and SKBR3 breast cancer cell lines
significantly hypersensitive to IR, but further ectopic expression
of miR-18a in ATM-depleted cells did not increase sensitivity to
IR (Figure 4B). These results suggest that ATM repression is
essential for the role of miR-18a in HRR and cell radiation
sensitivity.
To further investigate the biological role of miR-18a in the
progression of breast cancer, we examine the effect of miR-18a
on the ATM expression in primary normal breast epithelial cells
(NBECs). As shown in Figure S2A, ectopic expression of miR-18
Figure 2. miR-18a downregulated ATM expression via directly targeting the ATM 39-UTR. A, Predicted miR-18a target sequence in 39UTR
of ATM (ATM-39-UTR) and a mutant that contained two mutated nucleotides in the ATM 39-UTR (ATM-39-UTR -MUT). B, Western blotting analysis of
ATM expression in indicated cells transfected with miR-18a mimic- or miR-18a inhibitor-oligonucleotides. C, Western blot analysis that showed GFP
expression in indicated cells. a-Tubulin was used as the loading control. D, Luciferase assay on indicated cells that were transduced with the pGL3-
ATM-39UTR reporter with increasing amounts (10, 50 nM) of miR-18a mimic- or miR-18a inhibitor-oligonucleotides. E, Luciferase assay on indicated
cells transduced with pGL3-ATM-39UTR or pGL3-ATM-39UTR-MUT reporter with increasing amounts (10, 50 nM) of miR-18a mimic-oligonucleotides. F,
The expression (left) and correlation (right) of miR-18a and ATM in nine freshly prepared human breast cancer tissues. Error bars represent the mean
6 SD from three independent experiments. * P,0.05.
doi:10.1371/journal.pone.0025454.g002
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more, western blotting analysis revealed that, in response to IR
treatment, the expression levels of p-CHK2, H2AX (c-H2AX)
and p-53BP1 in the miR-18a transfected NBECs were much
lower that those in vector transfected control cells (Figure S2B).
Moreover, a clonogenic assay showed that overexpression of
miR-18a renders NBECs hypersensitive to IR (Figure S2C).
Taken together, our results suggest that upregulation of miR18a
in NBECs is sufficient to impair ATM activation and HRR
events upon IR treatment.
Inhibition of miR-18a Increased ATM Expression and
Reduced Cell Sensitivity to Irradiation
Next, we examined the effect of inhibiting miR-18a on the
ATM expression and HRR. As shown in Figure 5A, suppression of
miR-18a after the transfection of miR-18a inhibitor not only
increased the expression of ATM in both breast cancer cell lines,
but also dramatically increased the levels of phosphorylation levels
of H2AX (c-H2AX) and 53BP1 (p-53BP1). Furthermore, we
found that the inhibition of miR-18a significantly augmented the
frequency of HRR and reduced the proportion of cells that were
Figure 3. miR-18a impaired the ATM signaling pathway. A, Western blotting analysis of ATM expression, phosphorylated CHK2 (p-CHK2) and
total CHK2 protein in indicated cells treated with or without IR. a-Tubulin was used as the loading control. B, Western blotting analysis of the
expression levels of c-H2AX, phosphorylated 53BP1 (p-53BP1) and total 53BP1 protein in indicated cells treated with IR (2.0 Gy). a-Tubulin was used
as the loading control. C and D, The representative pictures (left panel) and quantification (right panel) of IR (2.0 Gy)-induced c-H2AX (C) and 53BP1
(D) foci were analyzed in indicated breast cancer cells transfected with NC, miR-18a or scramble ATM-siRNA. The foci numbers of at least 300 cells
were counted. Error bars represent the mean 6 SD from three independent experiments. * P,0.05.
doi:10.1371/journal.pone.0025454.g003
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PLoS ONE | www.plosone.org 5 September 2011 | Volume 6 | Issue 9 | e25454Figure 4. miR-18a reduces cell HRR frequency and enhances cell radiation sensitivity. A, DSB-induced HRR assay indicated that the
overexpression of miR-18a decreased the spontaneous HR frequency in HT1080-1885 cells. Western blotting analysis of the expression levels of ATM
and HA-tagged I-SceI endonuclease. a-Tubulin was used as the loading control. B, Overexpressing miR-18a or silencing ATM expression enhanced the
sensitivity of breast cancer cells to IR treatment. But further overexpressing miR-18a mimic had no additional sensitivity to IR in the ATM-silenced
cells. The viabilities of the indicated cells were assayed after indicated doses of c-radiation by the clonogenic cell survival assay. Error bars represent
the mean 6 SD from three independent experiments. * P,0.05.
doi:10.1371/journal.pone.0025454.g004
Figure 5. Inhibition of miR-18a increased cell HRR frequency and reduced radiosensitivity. A, Western blotting analysis of the expression
of ATM, c-H2AX, phosphorylated 53BP1 (p-53BP1) and total 53BP1 protein in indicated cells treated with IR (2.0 Gy). a-Tubulin was used as the
loading control. B, DSB-induced HRR assay indicated that inhibition of miR-18a increased the spontaneous HR frequency in HT1080–1885 cells.
Western blotting analysis of expression levels of ATM and HA-tagged I-SceI endonuclease. a-Tubulin was used as the loading control. C, Inhibition of
miR-18a reduced the sensitivity of breast cancer cells to IR treatment. The viabilities of the indicated cells were assayed after indicated doses of c-
radiation by the clonogenic cell survival assay. D and E, The representative pictures (left panel) and quantification (right panel) of IR (2.0 Gy)-induced
c-H2AX (D) and 53BP1 (E) foci were analyzed in indicated breast cancer cells transfected with either the NC or miR-18a inhibitor. The foci numbers of
at least 300 cells were counted.
doi:10.1371/journal.pone.0025454.g005
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immunofluorescence assay displayed that, upon IR treatment, the
foci numbers of c-H2AX and 53BP1 in the miR-18a inhibitor-
transfected cells were significantly increased (Figure 5D and 5E).
These results further supported the hypothesis that miR-18a
impaired DNA repair through the downregulation of ATM.
Discussion
The key finding of the current study is that miR-18a abrogated
IR-induced cell cycle arrest via repression of ATM. Bioinformatic
analysis and mechanistic studies revealed that miR-18a post-
transcriptionally repressed ATM expression by directly targeting
the ATM 39-UTR. Furthermore, we demonstrated that, similar
with the effect of ATM siRNA, ectopic expression of miR-18a
impaired IR-induced DNA damage repair, enhanced radiosensi-
tivity, and reduced the frequency of HRR. Moreover, we found
that the phosphorylation levels and formation rates of nuclear foci
of H2AX and 53BP1, the downstream substrates of ATM kinase,
were significantly deceased in miR-18a overexpressing cells.
Taken together, our results suggest that miR-18a may play an
important role in the regulation of ATM.
In mammalian cells, the most serious form of DNA damage is
double strand breaks, which act as potent triggers of DNA damage
response [27]. This type of DNA damage can arise from
exogenous agents, such as ionizing radiation (IR) and certain
genotoxic chemicals and endogenous stresses, including reactive
oxygen species (ROS) and mechanical stress on the chromosomes
[28]. To counteract the potentially deleterious effects of DNA
damage, cells have evolved two distinct pathways for the repair of
DSBs, known as homologous recombination (HR) and nonho-
mologous end joining (NHEJ) [29–30]. Among these two
pathways, homologous recombination repair (HRR) is mainly
promoted by the serine/threonine protein kinase, ataxia-telangi-
ectasia mutated (ATM), whose activity loss would result in low
efficiency of HR-mediated DSBs repair [31-32].
Previously, a number of studies have reported on the
mechanisms of regulation of ATM expression. It has been shown
that, upon DNA damage treatment, E2F-1 directly targeted ATM
promoter and elevated the expression of ATM, accompanying by
an E2F-induced increase in p53 phosphorylation [25]. It has been
also found that aberrant methylation of multiple CpG dinucleo-
tides within the proximal promoter region of the ATM gene results
in downregulation of ATM expression and cellular hyper-
radiosensitivity [33-34], suggesting methylation of ATM promoter
might be an alternative mechanism for downregulation of ATM.
In the current study, through public available algorithms
(TargetScan and miRanda), we found that ATM protein kinase,
is theoretically the target gene of miR-18a. This was further
determined by three different methods. Western blotting analysis
showed that overexpression of miR-18a resulted in the decrease of
ATM protein and sequential downregulation of phosphorylation
level of ATM downstream genes, including CHK2, H2AX and
53BP1. Nuclear foci staining of c-H2AX and 53BP1 revealed that
the recruitment of ATM downstream effectors to DNA lesions was
decreased by miR-18a overexpession. The luciferase activity assay
and point mutation analysis demonstrated that the downregulation
of ATM was mediated by miR-18a through the ATM-39-UTR.
Collectively, our results uncover a new regulatory mechanism of
ATM expression in breast cancer.
miR-18a belongs to a large miR cluster oncomir-1, also called
the miR-17,92 cluster, which encodes total 5 miRNAs, including
miR-17, miR-19a, miR-20a, miR-19b and miR-92a. miR17-92
cluster was found to be upregulated in lymphomas and in multiple
type of solid tumors, such as breast, colon, lung, stomach, and
pancreas cancers [35–36]. The elevated expression of miR17-92
gene cluster could also be genome-caused as the miR17-92 gene
cluster genome locus was found to be amplified in hematopoietic
malignancies [37]. Meanwhile, it has been reported that miR17–
92 gene cluster transcript could be activated by c-myc, N-myc and
E2F families [38–40]. Interestingly, the expression levels of each
miRNA in the cluster is not exactly parallel with each other,
suggesting that processing or stability of the miRNAs is
differentially regulated [41]. Guil and colleagues have found that
RNA-binding protein hnRNP Al, which is overexpressed in breast
cancer, could facilitate Drosha-mediated processing of miR-18a
[42–43]. Previously, several studies have demonstrated that miR-
17,92 cluster plays important role in the progression and
development of breast cancer. It has been shown that overexpres-
sion of miR-17 promotes human breast cancer cell migration and
invasion through downregulation of HBP1 [44]. Suppression of
miR-17 and miR-20a could inhibit growth and invasion of breast
cancer cells via upregulation of tumor suppressor ZBTB4 [45]. Al-
Nakhle et al reported that overexpressing miR-19 in breast cancer
cells resulted in downregulation of ERbeta1 via direct targeting of
its 39-UTR [46]. In the current study, we demonstrated that miR-
18a reduced DNA damage repair signaling and increased cellular
radio-sensitivity by repression of ATM, which further support the
notion that miR17–92 cluster functions as oncomir.
In summary, the current study provides, for the first time, an
important link between miR-18a-impaired DNA damage response
and downregulation of ATM in breast cancer. Our findings
revealed the significance of miR-18a in regulating cell cycle
checkpoints, DSBs repair and radiosensitivity. Understanding the
precise role played by miR-18a in DNA damage response
processes will not only increase our knowledge of breast cancer
progression but miR-18a might also be a signature of the DNA
damage response decision and a potential therapeutic target.
Materials and Methods
Ethics Statement
This study was conducted on a total of 19 breast cancer samples
that were histopathologically and clinically diagnosed at the Sun
Yat-sen University Cancer Center from 2009 to 2010. For the use
of clinical materials for research purposes, prior patients’ consents
and approval were obtained from the Sun Yat-sen University and
Cancer Center Institutional Board. All samples were collected and
analyzed with prior written informed consents from the patients.
Primary NBEC was isolated from the mammoplasty material of a
30-year-old woman and approved by the Sun Yat-sen University and
First Affiliated HospitalInstitutional Board. Samplewascollected and
analyzed with writteninformed consent.Primary NBEC wascultured
i nt h eK e r a t i n o c y t es e r u m - f r e em e d i u m( I n v i t r o g e n ,C a r l s b a d ,C A )
supplemented with epithelial growth factor, bovine pituitary extract
and antibiotics (120 mg/ml streptomycin and 120 mg/ml penicillin).
Breast cancer cell lines, MDA-MB-231 and SKBR3 were grown in
DMEMmedium(Invitrogen,Carlsbad,CA)suwith10%fetalbovine
serum (FBS) (HyClone, Logan, UT) and 100 units of penicillin-
streptomycin. Cells were maintained and experiments were accom-
plished in a humidified 37uCw i t h5 %C O 2.
RNA Extraction, Reverse Transcription (RT) and Real-time
PCR
Total miRNA from cultured cells and fresh surgical breast
cancer tissues was extracted using the mirVana miRNA Isolation
Kit (Ambion, Austin, TX, USA) according to the manufacturer’s
instructions. cDNA was synthesized from 5 ng of total RNA using
miR-18a Is Involved in DNA Damage Response
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Foster City, CA), and the expression levels of miR-18a were
quantified using miRNA-specific TaqMan MiRNA Assay Kit
(Applied Biosystems). Real-time PCR was performed using the
Applied Biosystems 7500 Sequence Detection system. The
expression of miR-18a was defined based on the threshold
cycle (Ct), and relative expression levels were calculated as
2
2[(Ct of miR218a) 2 (Ct of U6)] after normalization with reference to
expression of U6 small nuclear RNA.
Western Blotting
Western blotting was performed according to standard methods
as described previously [47], using anti-ATM, anti-CHK2, and
anti-p-CHK2 antibodies, anti-53BP1, anti-p-53BP1 (Cell Signal-
ing, Danvers, MA), anti-c-H2AX (Abcam, Cambridge, MA), anti-
HA (Sigma, Saint Louis, MI). The membranes were stripped and
re-probed with an anti-a-tubulin antibody (Sigma, Saint Louis,
MI) as a loading control.
Plasmids, siRNA and Transfection
The region of human ATM 39-UTR, from 3340 to 3540,
generated by PCR amplification from DNA of the SKBR3 cells,
was cloned into pEGFP-C1 (Clontech, Mountain View, CA)
and pGL3 vector (Promega, Madison, WI). The primers selected
were as the following: ATM-39UTR-GFP-up:GCCAGATCTT-
GAGAAATATAGAGATGTG;ATM-39UTR-GFP-dn:GCCGA-
ATTCGCTTTTAGAATTATT;ATM-39UTR-luc-up:GCCCC-
GCGGGAAATATAGAGATGTG;ATM-39UTR-luc-dn:GCC-
CTGCAGGCTTTTAGAATTATT;ATM-39UTR-MUT-luc-up:
GTATTTTAATTGCACCTTAATGAAATTATCTATT;ATM-
39UTR-MUT-luc-dn:AATAGATAATTTCATTAAGGTGCAA-
TTAAAATAC. For depletion of ATM, the siRNA was synthesized
and purified by Ribobio Inc. (Guangzhou, Guangdong, China).
The ATM siRNA sequence used was: TGGTGCTATTTACG-
GAGCT. Transfection of siRNAs or plasmids was performed using
the Lipofectamine 2000 reagent (Invitrogen) according to the
manufacturer’s instruction.
Luciferase Assay
Cells (3.5610
4) were seeded in triplicates in 48-well plates and
allowed to settle for 24 h. One hundred nanogram of luciferase
reporter plasmids or the control-luciferase plasmid, plus 10 ng of
pRL-TK renilla plasmid (Promega, Madison, WI), were trans-
fected into cells using the Lipofectamine 2000 reagent (Invitrogen
Co., Carlsbad, CA) according to the manufacturer’s recommen-
dation. Luciferase and renilla signals were measured 48 h after
transfection using the Dual Luciferase Reporter Assay Kit
(Promega, Madison, WI) according to a protocol provided by
the manufacturer. Three independent experiments were per-
formed and the data are presented as mean 6 SD.
Bromodeoxyuridine Labeling (BrdUrd Incorporation Assay)
To analyze the S-phase checkpoint, cells grown on coverslips (Fisher
Scientific) at 70% confluence were irradiated with the indicated dose
and incubated for 20 h. BrdUrd was added to cells and incubated for
2 h. Cells were then fixed and stained with anti-BrdUrd antibody
(Upstate, Temecula, CA) according to the manufacturer’s instructions.
Gray level images were acquired under a laser scanning microscope
( A x i o s k o p2p l u s ,C a r lZ e i s sC o .L t d . ,J e n a ,G e r m a n y ) .
Immuno fluorescence
Cells grown on coverslips (Fisher Scientific) were fixed in ice-
cold methanol for 10 min, blocked with 10% goat serum in PBS,
and incubated with anti-c-H2AX, anti-53BP1, in 10% goat
serum/PBS. The primary antibodies were detected with rhoda-
mine-conjugated goat anti-rabbit IgG (The Jackson Laboratory)
and the DNA was stained with DAPI. Gray level images were
acquired under a laser scanning microscope (Axioskop 2 plus, Carl
Zeiss Co. Ltd., Jena, Germany).
Flow Cytometry Analysis
Cells were irradiated with the indicated dose and incubated for
20 h. All cells were then harvested by trypsinization, washed in
ice-cold PBS, and fixed in 80% ice-cold ethanol in PBS. Before
staining, the cells were spun down in a cooled centrifuge and
resuspended in the cold. Bovine pancreatic RNAase (Sigma-
Aldrich) was added at a final concentration of 2 mg/ml, and cells
were incubated at 37uC for 30 min, followed by incubation in
20 mg/ml of propidium iodide (Sigma-Aldrich) for 20 min at room
temperature. 50,000 cells were analyzed on a flow cytometer
(FACSCalibur; BD Biosciences).
Clonogenic Survival Assay
Cells were plated at 500 cells per well onto a six-well dish in
triplicate and then incubated for 24 h to allow settling. Cells were
treated with a series of IR dose (0, 2, 4, 6, 8Gy). Clonogenic
Survival Assay was performed according to the standard methods
described in [48].
DSB-induced HRR Assay
HRR was assayed essentially as described previously [49].
Briefly, HT-1080–1885 cells were transfected with miR-18a mimic
or negative control mimic anlong with pCMV(HA-3xNLS)I-SceI
that expresses a HA epitope- and nuclear localization signal-
tagged I-SceI nuclease. Forty-eight hours later, ,100,000 viable
cells were transferred to 10-cm-diameter dishes, and HRR
products were selected in growth medium with 325 mg of G418/
ml. G418-resistant colonies were scored 12 to 14 days later. The
plating efficiency was determined by seeding the appropriate
numbers of cells to 10-cm-diameter dishes with growth medium
lacking G418. HRR frequencies were calculated as the number of
G418-resistant colonies per viable cell plated in G418 medium.
Background HR levels were estimated in parallel experiments,
except that cells were transfected with an empty pCMV vector.
Supporting Information
Figure S1 ATM expression in breast cancer cells and
inverse correlation between miR-18a expression and
ATM expression. Western blotting analysis of ATM expression
(left) and correlation (right) of miR-18a expression and ATM
expression in normal breast epithelial cells (NBEC) and breast
cancer cell lines, including ZR-75-1, ZR-75-30, SKBR3, T47D,
MDA-MB-231, MDA-MB-435, MDA-MB-453, BT474 and
BT-549.
(TIF)
Figure S2 Overexpression of miR18a is sufficient to
impair ATM activation and HRR events in response to
IR in NBECs. A, Western blotting analysis of the expression of
ATM in NBECs transfected with NC or miR-18a. a-Tubulin was
used as the loading control. B, Western blotting analysis of the
expression phosphorylated CHK2 (p-CHK2), total CHK2,
phosphorylated 53BP1 (p-53BP1), total 53BP1 and c-H2AX
protein in NBECs in response to IR (2.0 Gy) treatment. a-Tubulin
was used as the loading control. C, Overexpression of miR-18a
increased the sensitivity of NBECs to IR treatment. The viabilities
miR-18a Is Involved in DNA Damage Response
PLoS ONE | www.plosone.org 8 September 2011 | Volume 6 | Issue 9 | e25454of the indicated cells were assayed after indicated doses of c-
radiation by the clonogenic cell survival assay.
(TIF)
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